Importance of Increasing Modifiable Risk Factors Knowledge on Alzheimer's Disease Among Community Pharmacists and General Practitioners in Spain.
ADKS
Alzheimer’s disease
community pharmacist knowledge
general practitioner knowledge
knowledge scale
risk factors
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2019
2019
Historique:
received:
13
04
2019
accepted:
05
07
2019
entrez:
3
9
2019
pubmed:
3
9
2019
medline:
3
9
2019
Statut:
epublish
Résumé
Community pharmacists and general practitioners have daily contact with patients with Alzheimer's disease (AD) but the number of positive cases constantly increases every day. Thus, the aim of this research is to describe the level of AD knowledge among community pharmacists and general practitioners in Spain, in order to see where the biggest gaps in the knowledge are. Therefore, a cross-sectional study has been carried out, using the Alzheimer's disease knowledge survey (ADKS), among members of the Spanish Society of Primary Care Physicians and the Spanish Society of Family and Community Pharmacy to report the differences in AD knowledge in both professional collectives. The ADKS has been responded by 578 community pharmacists and 104 general practitioners and consists of a battery of 30 questions, whose possible answers are true or false. It assesses the AD knowledge in seven areas (impact on the disease, risk factors, course of the disease, diagnosis, care, treatment and symptoms). Results indicate that Spanish pharmacists and general practitioners have a high personal knowledge of AD, nevertheless, it is not associated with greater awareness. Both scored above 80% at the categories: diagnostic, treatment and symptoms. However, lower knowledge level (60% of correct answers) was found in those related to risk factors, such as the ignorance about hypercholesterolemia or hypertension as risk factors for the disease. Community pharmacists are already acting to control cardiovascular risk factors, but a wider knowledge of the relationship of these factors to AD is needed to act against these silent risk factors. Thus, pharmacists may also be involved in the management of AD that includes recognizing early symptoms for early detection of cognitive impairment. Hence, knowledge about risk factors is very important in developing this expanding role.
Identifiants
pubmed: 31474852
doi: 10.3389/fphar.2019.00860
pmc: PMC6704342
doi:
Types de publication
Journal Article
Langues
eng
Pagination
860Références
Alzheimers Dement (Amst). 2017 Feb 09;7:69-87
pubmed: 28275702
BMC Health Serv Res. 2017 Mar 21;17(1):224
pubmed: 28327136
Arch Neurol. 2005 Oct;62(10):1556-60
pubmed: 16216938
Gerontologist. 2009 Apr;49(2):236-47
pubmed: 19363018
BMC Health Serv Res. 2008 Apr 02;8:71
pubmed: 18384675
Am J Alzheimers Dis Other Demen. 2015 Feb;30(1):98-100
pubmed: 25425736
Rev Neurol. 2018 Jun 1;66(11):377-386
pubmed: 29790571
Neurologia (Engl Ed). 2021 Jul-Aug;36(6):426-432
pubmed: 34238525
J Am Pharm Assoc (2003). 2008 Nov-Dec;48(6):715-21
pubmed: 19019799
Rev Esp Geriatr Gerontol. 2018 Jan - Feb;53(1):26-37
pubmed: 29107401
Arch Intern Med. 2011 Sep 12;171(16):1441-53
pubmed: 21911628
Lancet. 2018 Nov 10;392(10159):2052-2090
pubmed: 30340847
Int J Geriatr Psychiatry. 2008 Jul;23(7):663-9
pubmed: 18229882
Front Pharmacol. 2018 Oct 29;9:1232
pubmed: 30420808
Aging Ment Health. 2012;16(7):828-35
pubmed: 22416945
Ann Neurol. 2013 Feb;73(2):170-9
pubmed: 23443990
Aust Fam Physician. 2009 Aug;38(8):642-9
pubmed: 19893788
Circulation. 2014 Apr 15;129(15):1560-7
pubmed: 24687777
Int J Geriatr Psychiatry. 2005 Apr;20(4):377-86
pubmed: 15799080
Aging Ment Health. 2012;16(4):521-8
pubmed: 22129312
Ther Adv Drug Saf. 2015 Aug;6(4):151-65
pubmed: 26301069
BMC Geriatr. 2013 Jan 02;13:2
pubmed: 23282030
Front Pharmacol. 2017 Oct 26;8:739
pubmed: 29123479